Genome-wide Association Study of Long COVID

Competing Interest Statement

Elizabeth T Cirulli: AB, KMSB, SW, NLW, FT, ES, and ETC are employees of Helix. Andreas Dinkel: AD received a honorarium from Gilead Sciences. Vince Forgetta: VF is an employee of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. Anna L Guyatt: ALG has a funded research collaboration with Orion for collaborative research projects outside the submitted work. Thompson Hannah: Options in Sano Genetics Catherine John: CJ has a funded research collaboration with Orion for collaborative research projects outside the submitted work. Kerstin U Ludwig: KUL is co-founder and member of the scientific board of LAMPseq Diagnostics GmbH. Tomoko Nakanishi: TN has received speaking fee from Boehringer Ingelheim for talks unrelated to this research. Heath E O'Brien: Options in Sano Genetics Limited. J. Brent Richards: JBR's institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. Patrick J Short: Share holder in Sano Genetics Limited. Christoph D Spinner: CDS reports grants, personal fees from AstraZeneca, personal fees and non-financial support from BBraun Melsungen, personal fees from BioNtech, grants, personal fees and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, personal fees from Eli Lilly, personal fees from Formycon, personal fees from Pfizer, personal fees from Roche, other from Apeiron, grants and personal fees from MSD, grants from Cepheid, personal fees from GSK, personal fees from Molecular partners, other from Eli Lilly, personal fees from SOBI during the conduct of the study; personal fees from AbbVie, personal fees from MSD, personal fees from Synairgen, grants and personal fees from ViiV Healthcare, outside the submitted work. Louise V Wain: Research collaborations and/or consultancy relationships with GSK, Genentech and Galapagos. All other authors have declared no competing interest.

Funding Statement

This study is a global research collaboration funded by various parties. Detailed funding information for each contributing study/author is provided in the author information supplement (Acknowledgements field).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Participants provided informed consent to participate in the respective study, with recruitment and ethics following study-specific protocols approved by their respective Institutional Review Boards (Details are provided in Extended Table S2).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes